Karyopharm Therapeutics (NASDAQ:KPTI) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Karyopharm Therapeutics (NASDAQ:KPTI) released its quarterly earnings results on Wednesday. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.02, Zacks reports. Karyopharm Therapeutics updated its FY 2025 guidance to EPS.

Karyopharm Therapeutics Trading Up 2.2 %

Shares of KPTI stock opened at $0.63 on Wednesday. The firm has a 50-day moving average price of $0.67 and a 200 day moving average price of $0.76. Karyopharm Therapeutics has a twelve month low of $0.58 and a twelve month high of $1.70. The company has a market capitalization of $79.50 million, a price-to-earnings ratio of -0.55 and a beta of 0.06.

Wall Street Analysts Forecast Growth

KPTI has been the subject of several research reports. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, January 15th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $3.00 price target on shares of Karyopharm Therapeutics in a research note on Monday, February 10th. StockNews.com downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Finally, Piper Sandler boosted their target price on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Karyopharm Therapeutics has an average rating of “Moderate Buy” and an average target price of $5.00.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).